Drugs / HER3-DXd
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04676477 | Jun 2021 → Jan 2025 overdue | non-small cell lung carcinoma | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06445972 | Aug 2024 → May 2028 expected | esophageal cancer, gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04165070 | Dec 2019 → Feb 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06731907 | Mar 2025 → Mar 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06172478 | Feb 2024 → Sep 2027 expected | breast cancer, carcinoma of esophagus, cervical cancer, endometrial cancer +7 | Daiichi Sankyo | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06099639 | — | lung cancer | Daiichi Sankyo | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER3-DXd | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04165070 ↗ |
| Modality | Monoclonal antibody | “anti-HER3 monoclonal antibody” PMID 41088723 ↗ Oct 2025 |
| Route | Intravenous | “IV Infusion” NCT04165070 ↗ |